Through the partnership, HHS’ Biomedical Advanced Research and Development Authority will give Summit $32 million over two years to conduct two Phase 3 clinical trials of its experimental drug Ridinilazole.
The drugmaker is also eligible to receive a three-year extension on the contract with total potential funding of $62 million.
To learn more about C diff, click here.
More articles on infection control:
Study suggests possible link between repeat flu vaccination and miscarriage
Study: Antibiotic use may boost superbug spread in nursing homes
Pet store puppies sicken 39 people in multistate bacterial outbreak
